GSK to Cut up to 1,217 Jobs in Belgium, L’Echo Says
The company said the plan could affect up to 1,217 employees as it reorganizes certain operations, while factory workers remain exempt.
- On Wednesday, British biopharmaceutical company GSK announced plans to cut up to 1,217 jobs across its Belgium locations, specifically excluding factory workers from the reorganization.
- These layoffs are part of a $2.5 billion global restructuring plan spanning three years to reallocate capital toward late-stage R&D, following GSK's recent closure of a German manufacturing facility affecting about 650 roles.
- Reductions will occur at GSK Belgium sites in Rixensart, Wavre, and Gembloux, though the company noted it remains Belgium's largest biopharma employer with operations contributing over 50% of global vaccine production.
- GSK's vaccine business remains strong, with second-quarter sales growing 8% year-on-year, driven by Shingrix generating $1.2 billion and Arexvy surging more than 100% to $270 million.
- Streamlining research, manufacturing, and support operations via digital and automation tools is the company's stated goal, though GSK has not yet specified which exact roles will be impacted.
38 Articles
38 Articles
GSK Layoffs: Pharma Giant to Cut Up to 1,217 Jobs in Belgium Restructuring
British pharmaceutical company GSK plans to eliminate up to 1,217 jobs in Belgium as part of a global restructuring and cost-saving initiative. Affected roles will primarily impact support and administrative staff across various sites, excluding factory workers. Despite the cuts, GSK remains Belgium's largest biopharma employer. GSK Layoffs: Pharma Giant to Cut Up to 1,217 Jobs in Belgium Restructuring.
The British laboratory announced this summer a plan to save money.
BRITISH GSK is cutting up to 1,217 jobs in Belgium as part of a €2.2 billion cost-savings plan to speed up the development of innovative medicines.
Its subsidiary GSK Belgium, which has more than 8,000 employees, is one of the largest private employers in Wallonia, deployed on three sites in this French-speaking region. The restructuring, announced on Wednesday morning at an extraordinary works council, is therefore about 15% of the workforce. "The aim is to align the organisation and industrial capacities with the structural evolution of global demand for certain vaccines", the subsidiary …
In Belgium, the pharmaceutical company has more than 8,000 employees, and the restructuring could cover around 15% of the staff.
Coverage Details
Bias Distribution
- 47% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
